GlassScriptPhysician profile
Henry H Chong
NPI 1073515276
$10,501.25
in general payments reported to CMS, 2019-2025
33 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,758 · 2020: $1,081 · 2021: $2,136 · 2022: $1,608 · 2023: $1,339 · 2024: $1,285 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,918.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,630.71 | 2019-2025 | |
| Amgen INC. | $1,185.48 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $942.64 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $772.42 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $720.15 | 2019-2022 | |
| Pfizer INC. | $612.94 | 2019-2025 | |
| Boston Scientific Corporation | $577.91 | 2019-2025 | Watchman Access System, Watchman Flx, Cds - Mct/Cem Monitoring |
| Merck Sharp & Dohme LLC | $568.70 | 2021-2025 | Verquvo, Winrevair |
| Janssen Pharmaceuticals, INC | $530.02 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $504.71 | 2019-2024 | Wainua |
| E.R. Squibb & Sons, L.L.C. | $485.92 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $374.78 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $218.30 | 2021-2025 | |
| Novo Nordisk INC | $188.42 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $172.31 | 2024-2025 | Aveir, Confirm Rx |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $150.57 | 2020-2023 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $127.66 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $123.55 | 2019-2021 | |
| Esperion Therapeutics, INC. | $120.94 | 2020-2025 | Nexletol |
| Arbor Pharmaceuticals, INC. | $106.41 | 2021 | |
| United Therapeutics Corporation | $75.22 | 2019-2021 | |
| Philips North America LLC | $68.82 | 2020-2024 | (Ck4) Mcot |
| Cvrx, INC. | $41.97 | 2024 | Barostim Neo System |
| Glaxosmithkline, LLC. | $36.14 | 2025 | Arexvy, Shingrix |
| Mannkind Corporation | $34.52 | 2025 | |
| Edwards Lifesciences Corporation | $32.36 | 2024 | Sapien 3 Ultra Resilia |
| Baxter Healthcare | $20.76 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Inspire Medical Systems, INC. | $15.03 | 2024 | Inspire |
| Astellas Pharma US INC | $14.18 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $13.51 | 2023 | Inpefa |
| Vivaquant INC, Dba Rhythm Express | $13.00 | 2025 | Rhythm Express |
| Gilead Sciences, INC. | $11.45 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9.75 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Chong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.